• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
LIU Jin,YANG Zongtong,SUI Zaiyun,YANG Qing.Effects of compound paeonol nanoemulsion on human lung cancer A549 in nude mice[J].Journal Of Pharmaceutical Research,2021,40(2):71-73,93[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 2495times   Download 3185次 QR Code for this article
Scan with your phone!
复方丹皮酚纳米乳对裸鼠体内人源肺癌A549的影响
刘瑾,杨宗统,隋在云,杨青
Font:Larger+|Default|Smaller-
(山东省中医药研究院中药药效评价重点实验室,山东 济南 250014)
摘要:
目的 研究复方丹皮酚纳米乳对裸鼠体内人源肺癌 A549 的影响及部分机制研究。方法 建立裸鼠人源肺癌 A549 移植瘤模型,灌胃给予不同剂量的复方丹皮酚纳米乳(48、96和192 mg·kg-1),观察其对A549移植瘤的治疗作用,每5 d使用游标卡尺测量裸鼠移植瘤的最长径和最短径,动态观察裸鼠移植瘤的生长情况,并计算其体积,以此绘出裸鼠移植瘤生长曲线。通过酶联免疫吸附法测定血清中白介素 2(interleukin-2,IL-2)和肿瘤坏死因子α(tumor necrosis factor-α,TNF-α)的水平,初步探讨其作用机制。结果 所有治疗组均对裸鼠 A549 移植瘤肿瘤体积、肿瘤体积增长率有一定的抑制作用,且随剂量的增加,抑制作用更强;与荷瘤对照组比较,复方丹皮酚纳米乳高剂量组和康莱特注射液组血清IL-2表达明显升高(P<0.01,P<0.01),复方丹皮酚纳米乳中、高剂量组和康莱特注射液组TNF-α表达水平明显升高(P<0.05,P<0.01,P<0.01)。结论 复方丹皮酚纳米乳对人源肺癌A549裸鼠移植瘤具有一定的抑制作用,其作用机制可能与促进细胞因子IL-2和TNF-α的表达有关。
关键词:  复方丹皮酚纳米乳  裸鼠  人源肺癌A549  白细胞介素2  肿瘤坏死因子α
DOI:10.13506/j.cnki.jpr.2021.02.001
基金项目:山东省重点研发计划项目(No.2015GSF119030);泰山学者工程专项经费项目(No.Ns201511107);山东省中医药科技发展计划(No.2013-118、2015-169);山东省重大科技创新工程项目(No.2018CXGC1301)
Publication Date:February 25, 2021
Effects of compound paeonol nanoemulsion on human lung cancer A549 in nude mice
LIU Jin,YANG Zongtong,SUI Zaiyun,YANG Qing
(Key Laboratory of Efficacy Evalution of Traditional Chinese Medicine,Shandong Academy of Chinese Medicine,Jinan 250014,China)
Abstract:
Objective To study the effects of compound paeonol nanoemulsion on human lung cancer A549 in nude mice andexplore the possible mechanisms.Methods An xenograft model of human lung cancer A549 in nude mice was established,different doses of compound paeonol nanoemulsion groups (48, 96 and 192 mg·kg-1 ) were administered by gavage to observe the therapeutic effect against A549 xenograft tumor.In order to dynamically observed the growth of transplanted tumors,the longest and shortest diameters of transplanted tumors were measured by vernier caliper every 5 days and the volume was calculated to plot the growth curve of transplanted tumors in nude mice.The levels of interleukin-2(IL-2) and tumor necrosis factor-α(TNF-α) in serum were measured by ELISA to explore the therapeutic mechanism initially.Results The tumor volume and tumor volume growth rate of the A549 xenograft tumor in the nude mice were inhibited in all treatment groups and the inhibiting effects strengthened following with the dosage increasing. Compared with the tumor-bearing control group, the IL-2 levels in serum of compound paeonol nanoemulsion high-dose group and Kanglaite injection group were significantly increased (P<0.01,P <0.01);theTNF-αlevels in serum of Kanglaite injection group,compound paeonol nanoemulsion middle-and high- dose groups were significantly increased(P<0.01,P<0.05,P<0.01).Conclusion Compound paeonol nanoemulsion had inhibitory effect on human lung cancer A549 in nude mice, and its mechanism may be related to promoting the expression of cytokines IL-2 and TNF-α.
Key words:  Compound paeonol nanoemulsion  Nude mice  Human lung cancer A549  Interleukin-2  Tumor necrosis factor-α
Today's Visits:483    Total Visits:2383194
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.